"Applikate has developed a unique approach to pathology that accelerates diagnosis, eliminates costs, and negates the need for wax embedding and toxic agents. I believe the company will disrupt the field of histology."
Applikate Technologies provides an elegant solution to the difficult and time-consuming problems faced by pathologists and their staff. The company’s solution offers a revolutionary approach to histology without requiring new skills, extensive training, or prohibitive costs. This technology has not yet been cleared by FDA for diagnostic use and is currently for Research Use Only.
William Tunstall-Pedoe is an entrepreneur who founded the British voice-assistant company Evi, which was purchased by Amazon in 2012 and became the basis for Amazon Alex and Echo devices. William mentors and invests in innovative startups and has holdings in more than 70 companies.
John Turner trained as resident and fellow at Duke University University Medical Center receiving his boards in Anatomic, Clinical, and Dermatopathology. A practicing pathologist, he is the HCA/ForwardPathology Solutions Capital Division Medical Director and Chief of the Medical Staff for CJW Medical Center. Dr. Turner is a medical advisor to Applikate.
Andrew is the co-founder of Gama, a deep space exploration company. He is an investor in over 60 companies across a range of industries, from synthetic biology to nuclear fusion. Previously, Andrew built Westwing, a publicly listed home and living ecommerce business across Europe, Russia, and Brazil. He is a veteran of Balderton Capital and McKinsey & Company.
Virginia Commonwealth University – School of Business
Master of Business Administration (MBA)
Virginia CommonwealthUniversity School of Medicine
Doctor of Medicine (M.D.)
Chemistry, Physical Chemistry
Investor, Physician, Medical Expert, and Business Advisor
Dick Hamrick is a pulmonary/critical care physician with a long history of diverse and broad leadership positions including as a Divisional Chief Medical Officer for HCA. Dr. Hamrick serves as a healthcare consultant and as an advisor/board member for Applikate and several early stage companies.
Investor, Physician, Medical Expert, and Professor
Ron Bridges is a Professor of Medicine and Gastroenterologist at the Cumming School of Medicine, University of Calgary. He has held several senior leadership roles, authored more than 40 papers and is actively involved as a mentor at the Creative Destruction Lab. Ron is an angel investor with an interest in medical devices and health care innovations.
Bachelor of Science, Health Information Management
Investor, Information Technology Expert, and Business Advisor
Julie is CIO of Ensemble IP and an investor in Applikate. She has extensive experience managing software development, software implementation, data science, and IT security projects. Previously, she led a Health Information Management (HIM) department; and provided consulting, implementation, and training services as part of the delivery of HIM software to hospitals and clinics worldwide.
Donald Plewes is Professor Emeritus from the Department of Medical Biophysics of the University of Toronto. His career has been devoted to research in the physics of medical imaging and has included x-ray imaging, computed tomography, ultrasound, and magnetic resonance imaging with clinical applications. His research proceeds from bench science and clinical trials; and has led to the successful commercialization of advanced technologies for breast screening and magnetic resonance imaging.
Dr. Plewes has published widely, holds numerous patents, and is an investor in and expert advisor to Applikate Technologies.
Royal Military College of Canada/Collège militaire royal du Canada
BEng, Mechanical Engineering
Royal Roads University
BEng, Mechanical Engineering
Investor, Astronaut, and Technology Expert
Chris Hadfield is an engineer, military fighter/test pilot and thrice-flown astronaut, having done two spacewalks and commanded the International Space Station. He is an advisor/director for multiple high-tech companies, and leads the Space stream at the Creative Destruction Lab tech incubator. Chris is a four-time internationally best-selling author, a professor at U Waterloo and online at Masterclass, and has created/hosted TV series with both BBC and National Geographic. Chris is an investor in Applikate Technologies and serves as an advisor to the company.
Eben Olson, Ph.D. is an Associate Research Scientist in the Department of Laboratory Medicine at Yale University, where he has been a member since 2013. His graduate degree is in Applied Physics with a focus on Biomedical Optics. Eben has been performing research involving development of software tools and methods for processing, visualization, and analysis of large image datasets. He is a core contributor to neural network framework modules in Python and has competed successfully in a number of data science competitions on kaggle.com and drivendata.org. He has extensive experience in electronics, machining, CAD, and optical design, having constructed several advanced multiphoton microscopes including design of control boards, optical element assembly, and embedded control software as well as having written Applikate’s StackStreamer software. In part through management of the engineering and clinical consultants. His primary responsibilities include engineering development, software conversion efforts, technical assessments and performance monitoring, component fabrication, hardware and software systems installations during clinical study, and directing engineering support during data acquisition.
William & Mary – Raymond A. Mason School of Business
William & Mary
David Hunt, MBA
Dave Hunt is Executive Chairman of Applikate. He is also the CEO and majority shareholder at Ensemble IP. Previously, he owned and led Landon IP, a large professional patent search and analytics company with operating offices in the United States, Japan, United Kingdom, Germany, India, and China. He is an early-stage investor in several medical device and AI-focused companies and led the Seed Series round for Applikate Technologies. He leads the business functions of Applikate and chairs the Board of Directors. He is a graduate of the College of William & Mary (B.A., ‘87, M.B.A, ‘93) and the Harvard Business Analytics Program (’19). Dave speaks English and Japanese.
Doctor of Philosophy – PhD, Computation and Neural Systems
University of Rochester
BS in Optics, Optics/Optical Sciences
Michael Levene, Ph.D.
Michael Levene pioneered the combination of multiphoton microscopy, the optical clearing of tissue and its application to pathology. He served on the faculty of Yale University from 2004 to 2014, after which he co-founded Applikate. Michael holds 20 granted U.S. Patents, authored 32 publications, and raised more than $6.3 million in research support between 2007 and the present.
Prior to joining Yale, Michael was a Research Associate in Applied and Engineering Physics at Cornell University, where he worked with Prof. Watt Webb and co-invented zero-mode waveguides for single molecule DNA sequencing, the technological foundation of Pacific Biosciences, Inc.
Master of Science/Master of Philosophy– (MS/MPhil), Biomedical Engineering (Optics)
Bachelor of Science – BS, Chemical Engineering
Richard Torres, M.D.
Rick Torres is a pathologist and biomedical engineer with expertise in medical laboratory instrumentation. He is board certified in Clinical and Anatomic Pathology and has worked as an independent consultant on commercial medical diagnostic devices. His clinical interests include flow cytometry, pathology informatics, and next generation sequencing for hematologic malignancies, having served as medical director of clinical chemistry, hematology, immunology, and flow cytometry laboratories. Rick Torres co-invented the novel histology techniques and devices developed by Applikate, served on the faculty of Yale University, co-founded the company, serves as Co-CEO, and holds several seminal patents. He maintains an adjunct appointment at Yale where he continues to perform part-time clinical interpretative work.